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Abstract
Background: Interindividual differences in liver functions such as protein synthesis, lipid and carbohydrate
metabolism and drug metabolism are influenced by epigenetic factors. The role of the epigenetic machinery in
such processes has, however, been barely investigated. 5-hydroxymethylcytosine (5hmC) is a recently re-discovered
epigenetic DNA modification that plays an important role in the control of gene expression.
Results: In this study, we investigate 5hmC occurrence and genomic distribution in 8 fetal and 7 adult human liver
samples in relation to ontogeny and function. LC-MS analysis shows that in the adult liver samples 5hmC
comprises up to 1% of the total cytosine content, whereas in all fetal livers it is below 0.125%.
Immunohistostaining of liver sections with a polyclonal anti-5hmC antibody shows that 5hmC is detected in most
of the hepatocytes. Genome-wide mapping of the distribution of 5hmC in human liver samples by next-generation
sequencing shows significant differences between fetal and adult livers. In adult livers, 5hmC occupancy is
overrepresented in genes involved in active catabolic and metabolic processes, whereas 5hmC elements which are
found in genes exclusively in fetal livers and disappear in the adult state, are more specific to pathways for
differentiation and development.
Conclusions: Our findings suggest that 5-hydroxymethylcytosine plays an important role in the development and
function of the human liver and might be an important determinant for development of liver diseases as well as
of the interindividual differences in drug metabolism and toxicity.
Background
There are substantial interindividual differences in many
liver processes, including intermediary metabolism, pro-
tein synthesis, carbohydrate metabolism and the detoxi-
fication of drugs and other xenobiotics. With respect to
variation in drug metabolism, transport and toxicity,
much knowledge has been gained from studies investi-
gating genetic factors responsible for interindividual dif-
ferences. However, little is known regarding the role of
epigenetic factors, such as DNA modifications and their
influence on hepatic gene expression, function and
interindividual variation [1].
The epigenetic DNA modifications include methyla-
tion and hydroxymethylation of cytosine. For many
years, 5-methylcytosine (5mC) was believed to be the
only epigenetic modification of genomic DNA, often
referred to as ‘the fifth base’ of the genome. Recently, 5-
hydroxymethylcytosine (5hmC) was discovered as a
novel epigenetic factor in mammalian DNA that can
have a stable effect on gene transcription and has hence
been regarded as ‘the sixth base’ of the genome [2,3].
5hmC originates from an enzymatic oxidation of 5mC
by TET1, TET2 and TET3 proteins [2,4], which recog-
nize their substrate 5mC by the amino-terminal CXXC
zinc finger domain [5]. This reaction is dependent on
Fe2+ as well as a-ketoglutarate; the latter, in turn, is
dependent on the activity of either isocitrate dehydro-
genase IDH1 in the cytosol and peroxisomes or IDH2
and IDH3 in mitochondria [6,7]. Although other pro-
teins may also have some significance in establishing the
presence of genomic 5hmC, the TET and IDH proteins
seem to play a very important role as determinants of
the global 5hmC content.
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Hydroxymethylcytosine can serve as an intermediate
of active DNA demethylation if further oxidized by
TET enzymes to 5-formylcytosine (5fC) and then to
5-carboxylcytosine (5caC), which in turn is removed by
thymine-DNA glycosylase. The resulting abasic site is
repaired by the base excision repair mechanism, produ-
cing unmethylated cytosine [8,9]. The level of 5fC was
found to be extremely low in mouse embryonic stem
cells and brain cortex (0.02 to 0.002% from total cyto-
sine) [9,10]. Despite the recent progress in genome-wide
mapping of 5fC in mouse embryonic stem cells, there is
still no convincing evidence for its role as an epigenetic
modification [11,12]. In contrast, 5hmC is 10 to 100
times more abundant than 5fC and can stably persist in
vivo, thus serving as an epigenetic mark with unique
regulatory functions.
Several functional differences have been demonstrated
between the two DNA modifications 5mC and 5hmC.
Firstly, the vast majority of CpG sites throughout the
genome (except for those located in CpG islands and
shores) are constantly methylated. In contrast, 5hmC can
be found at only a relatively small subset of CpG sites.
Furthermore, variable methylation correlating with gene
expression has been described mostly in the promoter
regions, whereas the genomic distribution of 5hmC is
biased towards exonic regions. In addition, 5mC is, in
most cases, a repressive epigenetic mark, whereas the
presence of 5hmC correlates with active gene transcrip-
tion [13-21]. The latter observation can be explained by
the different affinity of 5mC and 5hmC for methylated
DNA binding proteins. It was demonstrated that MeCP1,
MBD1, MBD2 and MBD4 bind to methylated but not to
hydroxymethylated loci [22,23], whereas MBD3 binds to
5hmC with even higher affinity than it does to 5mC [24].
Moreover, the composition of DNA binding and histone
modifying proteins in 5hmC-containing loci can also be
very different from that of methylated DNA, thus result-
ing in different gene expression outcomes [16,18-20,25].
Highly variable levels of 5hmC have been detected in
many human and mammalian tissues and cell types with
characteristic tissue-specific patterns [14]. 5hmC is espe-
cially enriched in brain tissue and in embryonic stem
cells, where it constitutes up to 1 to 1.3% of the total
cytosine content [14,17,26-29]. Furthermore, 5hmC has
been shown to participate in neurodevelopment and has
been associated with pluripotent cell states [30-32]. In
cancers, such as prostate, breast, melanoma, glioma and
colon carcinoma, the content of 5hmC is significantly
decreased compared to normal tissue, is usually asso-
ciated with decreased TET or IDH expression and, more
importantly, can affect the tumor phenotype [7,14,33,34].
With respect to human liver, very little is known about
5hmC distribution and function.
In this study we demonstrate that adult human livers
contain high levels of 5hmC, which are comparable to
those found in the brain tissue. The analysis of genome-
wide 5hmC hepatic distribution revealed that 5hmC is
particularly enriched in coding regions of actively tran-
scribed genes. In addition, the results show profound
differences in both genomic distribution and global
5hmC content between fetal and adult liver samples.
These differences were further pronounced by pathway
analysis of genes enriched for 5hmC elements, which
clearly showed consistency with liver development, thus
suggesting that 5hmC may play an important role in
hepatic development and function.
Results
Global 5mC and 5hmC content in fetal and adult human
livers
Global levels of 5mC and 5hmC were determined in
eight fetal and seven adult human livers using liquid
chromatography-mass spectrometry (LC-MS) analysis,
based on calibration curves with known 5mC and 5hmC
content. The quantification range of 5hmC was from
0.0625 to 1.0% of total cytosine, suggesting our method is
highly sensitive. The linear standard curve has excellent
fit (R2 > 0.999; Figure S1 in Additional file 1). Therefore,
we used this calibration curve to determine global levels
of 5mC and 5hmC in eight fetal and seven adult human
livers. The 5mC and 5hmC contents of fetal and adult
samples are shown in Figure 1 (for details, see Table S2
in Additional file 1). The median 5mC content was 4.2%
of total cytosine in fetal livers and 5.3% in adult livers. By
contrast, much less 5hmC was found in fetal livers com-
pared to adult livers (Figure 1). All eight fetal samples
had a 5hmC content lower than 0.125%, whereas the sig-
nal from six out of seven adult samples was above 0.2%,
and the median 5hmC content for adults was 0.62% of
total cytosine.
Immunohistostaining of human liver samples
In order to explore the distribution of 5hmC in the liver,
we immunostained human liver sections for both this
cytosine modification as well as for 5mC. As depicted in
Figure 2, both 5mC and 5hmC were detected in the
nuclei of most hepatocytes within the liver tissue sections.
No significant difference regarding intranuclear localiza-
tion between 5mC and 5hmC was observed. Three-
dimensional analysis of the sections further revealed the
abundant distribution of 5hmC to the majority of hepato-
cytes (data not shown).
Quantification of TET1-3 and IDH1-2 transcripts
The observed differences in global 5hmC content
between fetal and adult cohorts may be explained by
Ivanov et al. Genome Biology 2013, 14:R83
http://genomebiology.com/2013/14/8/R83
Page 2 of 15
differences in expression of the TET and/or IDH
enzymes, which are involved in the conversion of 5mC
to 5hmC. The mRNA levels of TET1-3 and IDH1-2
were assessed by quantitative RT-PCR in 14 fetal and
33 adult livers, including the samples investigated by
LC-MS. Interestingly, the results showed a significant
decrease in all TET genes (P < 0.0001) in adult livers when
compared to fetal (Figure 3). However, the slight increase
in IDH1 (P = 0.0024) and IDH2 (P < 0.0001) in adult sam-
ples may potentially explain the higher total 5hmC content
in these livers compared to fetal 5hmC levels.
Genome-wide profiling of 5hmC
To investigate the genome-wide distribution of 5hmC,
we enriched the 5hmC-containing fraction of the DNA
samples from the eight fetal and seven adult human
livers. Both 5hmC-enriched DNA samples and their
non-enriched counterparts were ligated with adapters,
amplified and then subjected to next-generation sequen-
cing (NGS), as described in Materials and methods. The
main quality metrics of the NGS experiment as well as
the number of called 5hmC peaks for each liver sample
are listed in Table S3 in Additional file 1.
Figure 1 Total 5mC and 5hmC in fetal and adult livers as determined by LC-MS. The percentage of (a) 5mC and (b) 5hmC in relation to
the total cytosine content in eight fetal and seven adult livers is shown.
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Overall, the fetal liver samples showed significantly
fewer 5hmC peaks (11,366 to 32,522) covering a smaller
portion of the genome (10 to 40 Mb) compared to adult
samples (68,779 to 134,956 peaks covering 80 to 203
Mb). These results are in agreement with the finding by
LC-MS that global 5hmC content is lower in fetal livers
than in adults. Furthermore, the 5hmC peaks appear to
be unevenly distributed among chromosomes, being
over-represented on chromosomes 16, 17, 19 and
22 and under-represented on the sex chromosomes
(Figure S2 in Additional file 1).
When investigating the proportion of peaks that were
shared by samples belonging to each cohort, a small frac-
tion of peaks was shared by all fetal samples (2.5%) and
all adult samples (8.3%; Figure S3 in Additional file 1).
A large majority of the peaks were identified as unique
Figure 2 Immunostaining of human adult liver for 5mC and 5hmC. Representative stainings of 40 µM adult liver sections are shown. (a)
Negative control without the primary antibody. (b) Staining with the monoclonal antibody to 5mC (green) and DAPI (blue). (c) Staining with a
polyclonal antibody against 5hmC (red) and DAPI (blue). (d) Merge of 5mC and 5hmC staining and DAPI. As evident from (d), 5mC and 5hmC
show similar patterns of intranuclear distribution, indicating that 5hmC, when present, tends to co-localize with 5mC in the hepatocyte nucleus.
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peaks (54.4% in fetal and 36.1% in adult livers), suggest-
ing high interindividual variability in the genomic dis-
tribution of 5hmC. On the other hand, a significant
proportion of hydroxymethylation reproducibly appears
at the same genomic locations, as seen when comparing
5hmC peaks shared by more than one sample. Examples
of the distribution of 5hmC peaks in five different genes
are shown in Figure 4. We focused on the continuous
genomic intervals, or ‘5hmC blocks’, where 5hmC occu-
pancy was detected in at least two samples in a given
cohort (Figure 4a). In other words, ‘5hmC blocks’ repre-
sent genomic intervals that are prone to be hydroxy-
methylated in a given cohort (although not necessarily
hydroxymethylated in every sample in this cohort). In
contrast, the probability to detect 5hmC outside of 5hmC
blocks is relatively low. Of the five genes illustrated in
Figure 3 Expression levels of the TET1-3 and IDH1-2 genes in fetal and adult livers. Gene expression at the mRNA level was determined
using quantitative RT-PCR and specific primers in samples from 14 fetal and 33 adult livers and normalized against EIF2B2. The boxplots show
the relative gene expression in a log2-scale. The maximum length of each whisker is 1.5 times the interquartile range (IQR). The significance of
differences is indicated by asterisks: *P < 0.01, ***P < 0.0001.
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Figure 4 The distribution of 5hmC peaks in five liver genes. (a) A detailed view of the GSTK1 gene. For each 5hmC-enriched sample (y-axis),
the read depth is plotted against the genomic coordinates in the given interval (x-axis). The 5hmC peaks called by the MACS software are
shown by the short horizontal lines. The 5hmC blocks identified in this study are denoted by vertical rectangles. (b) Representative illustration of
the genomic positions of 5hmC peaks identified in the genes ARNT, ABCC4, FMO5 and ABCC13. The fetal peaks are shown in gray and the adult
peaks are shown in black.
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Figure 4, most had many more 5hmC blocks in adult
livers, whereas in the ABCC13 gene, 5hmC blocks were
mainly identified in fetal livers. The relation between this
variability and the differences in gene expression between
the livers has to await analyses in larger cohorts. The
full lists of fetal (n = 29,917) and adult 5hmC blocks
(n = 116,911) identified in this study are available in
Additional files 2 and 3, respectively.
Locus-specific validation of next-generation
sequencing data
To validate our NGS data, we profiled 5mC and 5hmC
content at single-base resolution for two randomly
selected genomic intervals in four fetal and four adult
liver DNA samples. The first interval (containing four
CpG sites overlapping with a fetal-only 5hmC block)
was located in intron 15 of the DROSHA gene, whereas
the second one (containing seven CpG sites) was located
in intron 2 of the CDH2 gene and manifested adult-only
hydroxymethylation. The results of the single-base ana-
lysis are shown in Figure S5 in Additional file 1. The
fetal hydroxymethylation in DROSHA (averaged over
four CpG sites in each sample) could reach up to 35%,
whereas in adult samples it did not exceed 4%. In con-
trast, fetal hydroxymethylation in CDH2 (averaged over
seven CpG sites) was never higher than 5%, whereas in
adult samples it varied between 49 and 56%. Thus,
despite the single false positive and false negative 5hmC
peaks identified for both genes, the 5hmC values
obtained from the validation experiment are in good
agreement with the NGS data.
Genomic and functional localization of 5hmC
Next, we investigated the possible enrichment of 5hmC
blocks in RefSeq genes, microRNA (miRNA) and long
non-coding RNA (lncRNA) genes, hepatic enhancers,
CpG islands (CGIs), CGI shores and repetitive
sequences. We found that both fetal and adult 5hmC
blocks are slightly enriched in RefSeq genes and strongly
enriched in enhancers, miRNA genes, CGIs and CGI
shores, but under-represented in lncRNA genes and
repetitive regions (Figure 5a). Furthermore, the relative
enrichment of 5hmC blocks in enhancers, miRNA
genes, CGIs and CGI shores is approximately double in
fetal samples compared to adults, whereas in RefSeq
genes and lncRNA genes as well as in repetitive regions
the rate of 5hmC enrichment remains nearly constant
during liver development.
To investigate if cytosine hydroxymethylation in
human liver correlates with active gene transcription, we
analyzed how 5hmC blocks are distributed among genes
with different expression levels. To this end, we quanti-
fied the genome-wide mRNA expression levels of
14 fetal and 86 adult liver samples (including all samples
employed in the NGS study). The analyzed 17,771
RefSeq genes were divided into low, intermediate and
highly expressed genes, separately for fetal and adult
cohorts. The relative enrichment of 5hmC blocks in
each of these three categories of genes is shown in
Figure 5b. Both fetal and adult 5hmC blocks are under-
represented in the genes with low expression or silent
genes, and over-represented in genes with intermediate
or high expression, suggesting a likely role for hydroxy-
methylation in active gene transcription.
5hmC localization during development
The observed profound differences in both global 5hmC
content and the number of called 5hmC peaks between
the fetal and adult liver samples suggest that 5hmC dis-
tribution is significantly modified during liver develop-
ment throughout the genome. When comparing the
fetal and adult hydroxymethylomes, we found 5,038
5hmC blocks present in fetal livers only and 96,097
blocks detectable only in adult samples. These fetal- and
adult-specific 5hmC blocks were then investigated for
their distribution among the following five gene groups:
I) fetal-specific genes (expressed in fetal samples, but
silent in adults; n = 464); II) genes expressed in fetal
samples at least two-fold higher than in adults (n =
805); III) non-developmentally expressed genes (n =
8,731); IV) genes expressed in adult samples at least
two-fold higher than in fetal samples (n = 1,079); and
V) adult-specific genes (expressed in adult cohort, but
silent in fetal cohort; n = 306). Relative enrichment
values of genic fetal-specific and adult-specific 5hmC
blocks in these groups of genes are shown in Figure 5c.
As evident from these data, fetal-specific 5hmC blocks
were seen strongly enriched in fetal expressed genes
(groups I and II) but not in non-developmental (group
III) or adult-specific genes (groups IV and V). Accord-
ingly, adult-only 5hmC blocks are strongly under-repre-
sented in fetal-only genes (group I), but skewed towards
genes that are exclusively expressed in the adult livers
(groups IV and V). Hence, developmental patterns of
hydroxymethylation correlate with developmental pat-
terns of gene transcription in human livers.
5-Hydroxymethylation in relation to gene function
Finally, genes intersecting with fetal-only or adult-only
5hmC blocks were annotated to specific biological path-
ways using the GREAT software. Those genes that
acquired hydroxymethylation in the adult state were
found to be involved in active catabolic and metabolic
processes, such as mRNA catabolic process, carbohy-
drate transport, fatty acid oxidation and lipid oxidation,
which is well in line with the function of the adult liver.
Meanwhile, the genes containing fetal-only 5hmC blocks
were more specific to pathways for differentiation and
Ivanov et al. Genome Biology 2013, 14:R83
http://genomebiology.com/2013/14/8/R83
Page 7 of 15
development, such as regulation of cell differentiation,
stem cell development, and establishment or mainte-
nance of cell polarity. The top 10 biological processes
for these two groups of genes are given in Table 1.
The comparison of human hepatic and cerebellum
hydroxymethylomes
We compared our data on fetal and adult hepatic hydro-
xymethylomes with the previously published 5hmC map
of the human adult cerebellum [30]. The study of Szul-
wach and colleagues [30] revealed 43,272 5hmC-con-
taining genomic intervals in the cerebellum, covering
15.1 Mb. Among them, 8.4 Mb (56%) do intersect with
the 5hmC blocks in adult liver. In addition, 3.3 Mb of
5hmC-containing sequences are shared between cerebel-
lum and fetal liver, and 2.7 Mb are common for all
these three tissues. Thus, these data indicate that, even
though 5hmC distribution is tissue-specific, some 5hmC
elements are conserved between different tissues and
developmental stages. Pathway analysis of these con-
served 5hmC elements reproducibly identified sterol
metabolism and insulin response genes among the top
10 pathways (Table S4 in Additional file 1).
Discussion
Our study reports, for the first time, the characteristics
of the 5hmC epigenetic modification in fetal and adult
human livers. We have quantified the global 5hmC con-
tent in fetal and adult human livers by LC-MS and
showed significantly higher levels of 5hmC in adult
compared to fetal samples, accompanied by a corre-
spondingly higher expression of IDH genes, known
5hmC regulators. Our investigations of the global geno-
mic distribution patterns of 5hmC using NGS categorize
this DNA modification as an important mark in hepatic
gene expression and development.
Until recently, quantification of 5hmC relied on less pre-
cise methods, mainly antibody detection techniques, and
utilized a very small sample size. For example, Li and Liu
[35] reported the 5hmC human liver content to be 0.45%
of total DNA (0.09% of total cytosine), whereas Nestor et
al. [14] reported values of approximately 0.22% of total
cytosines. LC-MS enables sensitive and reliable quantifica-
tion of 5hmC. Previous studies in murine livers found that
5hmC content quantified by LC-MS was very low (0.05 to
0.07% from the total cytosine) compared to other murine
tissues (for example, 0.3 to 0.7% in the central nervous sys-
tem [26]. Importantly, LC-MS quantification of 5hmC in
human liver, to our knowledge, has not been carried out
before. Utilizing LC-MS together with a protocol devel-
oped to detect both 5mC and 5hmC within the same tis-
sue sample, we were able to quantify the 5mC and 5hmC
content in seven adult and eight fetal livers. In contrast to
the data reported in mice, our results demonstrate that
Figure 5 Relative enrichment of 5hmC blocks in various genomic regions. (a) The relative enrichment of fetal and adult 5hmC blocks in
genomic features compared to H0 of random genomic distribution of 5hmC blocks. (b) The relative enrichment of fetal and adult 5hmC blocks
in groups of genes manifesting low, intermediate or high gene expression. (c) Enrichment of fetal-only and adult-only 5hmC blocks in groups of
genes manifesting different patterns of expression changes in liver development. The dashed line denotes the reference enrichment rate.
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5hmC levels in the majority of human adult livers (0.5 to
1% 5hmC) remain comparable to those found in the cere-
bral cortex (1 to 1.3% 5hmC), the most DNA-hydroxy-
methylated human tissue identified to date [14,29]. As
adult human livers have notably higher global 5hmC con-
tent than murine ones, mice are unlikely to serve as rele-
vant models for the human hepatic hydroxymethylome.
Moreover, LC-MS quantification of multiple liver samples
also demonstrated that the overall content of both 5mC
and 5hmC is variable between the samples.
Interestingly, fetal samples showed a significantly
lower 5hmC content and very similar levels of total
5mC when compared to adult livers. Drastic differences
in 5hmC levels between adult and fetal livers can sug-
gest that DNA hydroxymethylation is an important epi-
genetic phenomenon for liver development. The
observed increase of global 5hmC content in adult com-
pared to fetal livers is interesting because, in the major-
ity of studies, a high 5hmC content has been associated
with an embryonic or undifferentiated state of tissues or
cells. For example, Ruzov and co-authors [32] report
changes of 5hmC abundance in the development of
mouse and postulate that 5hmC is enriched in embryo-
nic context compared to adult tissues. Szwagierczak and
colleagues [28] showed significantly more 5hmC in
undifferentiated mouse embryonic stem cells than
in corresponding embryoid bodies, where the decrease
in 5hmC content during differentiation was attributed
to decreased expression of TET1. In addition, repro-
gramming of differentiated cells into induced pluripo-
tent stem cells activates TET enzymes and leads to
accumulation of 5hmC, where the link between 5hmC
levels and development was explained by the presence
of binding sites for pluripotency-associated transcription
factors (OCT4, SOX2) in the promoter of TET1 [13,31].
In contrast to these studies, our data indicate a decrease
in the extent of 5hmC modifications from the early
embryonic stages to adult liver. Similarly, Hahn and col-
leagues [36] showed that 5hmC is more abundant in
terminally differentiated neurons than in neural progeni-
tor cells, thus suggesting that the global 5hmC content
increases with terminal maturation in specific tissues.
Our studies revealed that the lower 5hmC content in
the fetal livers was accompanied by lower expression of
Table 1 Functional annotation of developmentally hydroxymethylated regions
Binomial test Hypergeometric test
Biological process Raw P-valuea FDR Q-valueb Fold enrichmentc FDR Q-valued Fold enrichmente
Genes enriched with adult-only 5hmC blocks
Nuclear-transcribed mRNA catabolic process 4.30E-182 3.22E-180 2.49 8.82E-03 1.16
mRNA catabolic process 8.88E-165 5.52E-163 2.25 1.77E-02 1.14
Carbohydrate transport 3.29E-125 1.51E-123 2.06 5.91E-03 1.15
Vesicle localization 9.48E-113 4.05E-111 2.20 3.73E-02 1.16
Fatty acid oxidation 5.52E-102 2.12E-100 2.22 4.59E-03 1.20
Lipid oxidation 1.44E-100 5.39E-99 2.20 3.97E-03 1.20
mRNA 3’-end processing 1.73E-98 6.27E-97 2.24 1.11E-02 1.17
Monocarboxylic acid catabolic process 1.35E-95 4.80E-94 2.21 5.31E-03 1.20
RNA 3’-end processing 2.92E-94 1.02E-92 2.07 2.13E-02 1.15
Fatty acid catabolic process 2.99E-90 9.99E-89 2.22 1.00E-02 1.20
Genes enriched with fetal-only 5hmC blocks
Regulation of granulocyte differentiation 5.88E-23 2.45E-20 6.20 3.56E-02 2.58
Regulation of myeloid cell differentiation 9.74E-17 1.67E-14 2.19 1.84E-03 1.64
Induction of apoptosis by extracellular signals 5.49E-15 7.18E-13 2.18 9.28E-03 1.54
Positive regulation of steroid metabolic process 1.76E-12 1.61E-10 3.87 9.82E-03 2.37
Stem cell development 6.00E-12 5.05E-10 2.09 4.16E-04 2.06
Establishment or maintenance of cell polarity 9.26E-11 6.14E-09 2.02 1.97E-02 1.63
Regulation of protein binding 6.32E-10 3.38E-08 2.03 2.36E-02 1.64
Stem cell maintenance 8.22E-10 4.31E-08 2.00 9.44E-04 2.04
Somatic stem cell maintenance 6.28E-09 2.59E-07 2.15 2.15E-02 2.04
Negative regulation of lipoprotein particle clearance 1.99E-07 6.11E-06 6.52 3.08E-02 3.73
Shown are the top 10 significantly enriched biological processes sorted according to the binomial P-values. aUncorrected P-value from the binomial test over
genomic regions; bfalse discovery rate q-value; cfold enrichment of number of genomic regions in the test set; dfalse discovery rate q-value from the
hypergeometric test over genes; efold enrichment of number of genes in the test set.
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the IDH1 and IDH2 genes, known regulators of 5hmC
level. Hence, it is tempting to speculate that the increase
of 5hmC in adult samples is due to the developmental
increase of IDH enzymes. However, we did not observe
any correlation between the individual 5hmC content
and the levels of either TET1-3 or IDH1-2 transcripts in
individual livers (data not shown), indicating that other
factors contribute to the global 5hmC content of human
liver. Thus, we cannot completely rule out the possibility
that the level of TET and/or IDH enzymes can be regu-
lated in a post-transcriptional or post-translational man-
ner, and the developmental burst of 5hmC is controlled
by mechanisms other than the increased expression of
IDH1 and IDH2 mRNA.
The observed abundance of 5hmC in adult livers and
its preferential localization in actively transcribed genes
suggest that bisulfite sequencing data from adult livers
should be considered with caution, as bisulfite conver-
sion does not distinguish between 5mC and 5hmC [37].
Hence, specific methods allowing discrimination
between these two cytosine modifications become espe-
cially important in human liver research.
NGS of 5hmC-enriched genomic DNA obtained from
fetal and adult liver samples revealed profound differ-
ences in the genomic distribution of 5hmC peaks
between the cohorts and significant interindividual var-
iation among samples within the groups. Interestingly,
the genomic distribution of 5hmC peaks did not occur
at random but appeared to be dependent on the geno-
mic context and on the stage of liver ontogeny. In gen-
eral, 5hmC is relatively under-represented in repetitive
sequences and enriched in coding regions of actively
transcribed genes (Figure 5a). In addition, 5hmC peaks
are even more enriched in CGI shores (and hence fre-
quently overlap with CGIs), which is in agreement with
the tendency of 5hmC to occur in regions with
increased CpG density (Figure S4 in Additional file 1).
These 5hmC distribution patterns are quite consistent
with previous reports for mammalian nervous tissue and
embryonic stem cells [13-17,19-21], suggesting a func-
tional role for 5hmC in the regulation of gene expres-
sion. In addition, the observed tendency of 5hmC peaks
to occur in coding genes and regions with increased
CpG density may explain the over-representation of
5hmC blocks on chromosomes 16, 17, 19 and 22 (Figure
S2 in Additional file 1). Moreover, the depletion of
5hmC from sex chromosomes as seen here has been
observed before in human embryonic stem cells and
mouse brain [16,30].
We found that 5hmC blocks in both fetal and adult
livers are strongly enriched in genes encoding miRNAs
and depleted within lncRNA genes, thus suggesting a
role for 5hmC in the regulation of the expression of
miRNA genes (Figure 5a). In addition, the observation
of high enrichment of 5hmC in hepatic enhancers sug-
gests that 5hmC could play a role in the regulation of
gene expression through distal regulatory elements.
Moreover, our results evidently indicate the involvement
of 5hmC in the developmental expression of protein-
coding genes in human liver. Fetal-only 5hmC blocks
(that is, genomic intervals that lose 5hmC during liver
development, despite the increasing genomic 5hmC con-
tent) are especially enriched within genes annotated as
belonging to developmental and differentiation-related
processes, whereas in adult livers, de novo acquired
5hmC appears to predominantly reside in genes asso-
ciated with hepatic metabolism. These data are in line
with the observation of Thomson and co-authors [38],
who recently described the dynamics of 5hmC and its
effect on gene expression in mouse livers. The authors
showed that following exposure to phenobarbital, rapid,
dynamic and reciprocal changes in the level of 5hmC
and 5mC occurred over the promotor regions of the
murine genes known to be transcriptionally regulated by
phenobarbital. The changes in hydroxymethylation and
methylation further coincided with changes in the his-
tone marks H3K4me2, H3K27me3 and H3K36me3, and
indicate that cytosine hydroxymethylation may be cru-
cial in the acute transcriptional regulation of specific
hepatic genes.
Here we provide the evidence that adult human liver
DNA contains a high level of 5hmC. The brain is
another differentiated human tissue that is highly hydro-
xymethylated [14,29]. We compared our hepatic 5hmC
data with the available cerebellum dataset, obtained
using the same chemical labeling-based method for
5hmC capture as in our study [30]. The results of path-
way analysis of 5hmC intervals that are shared between
cerebellum and fetal and adult human livers suggest
that the presence of specific 5hmC signatures within
genes related to sterol metabolism and insulin response
could be conserved between various tissues.
Conclusions
In this study, we for the first time demonstrate that, in
contrast to earlier reports, 5hmC is an abundant epige-
netic modification in adult human liver. Our findings on
the genomic distribution of 5hmC suggest that this epi-
genetic mark may be an important determinant of the
expression of both protein-coding and miRNA genes in
hepatocytes. Furthermore, 5hmC appears to play a sig-
nificant role in hepatic gene expression changes during
liver development. Hence, cytosine hydroxymethylation
may be a missing link in the full understanding of the
functional as well as the developmental processes of the
liver, and also can contribute to interindividual differ-
ences in liver function and susceptibility to liver disease.
Moreover, our findings suggest the importance of using
Ivanov et al. Genome Biology 2013, 14:R83
http://genomebiology.com/2013/14/8/R83
Page 10 of 15
methods that permit the discrimination between 5mC
and 5hmC when investigating the liver epigenome, as
the traditional methods based on bisulfite sequencing
can cause erroneous conclusions.
Materials and methods
Human tissues
Liver samples from fourteen 8- to 12-week-old fetuses
were acquired from Karolinska University Hospital (Hud-
dinge, Sweden). Fifty-two liver samples originate from
adult organ donors who met accidental death. Of these,
33 were acquired from Karolinska University Hospital,
and 19 were commercially purchased from XenoTech
(Lenexa, KS, USA) and the International Institute for the
Advancement of Medicine (IIAM; Edison, NJ, USA). This
work was carried out in compliance with the methods
within the Helsinki declaration. The use of fetal and
adult liver tissues for the purposes of this study was
approved by the Regional Ethics Committee. The refer-
ence numbers for the ethical approvals by the Karolinska
Institutet Internal Review Ethical Board are 2010/541-23/
1, 2010/541-31/1, 2010/678-31/3 and 280/00.
Nucleic acid purification and quantification
DNA and total RNA were isolated from the liver samples
using a AllPrep DNA/RNA/Protein Mini kit (QIAgen,
Germantown, MD, USA; catalogue number 80004). DNA
was quantified using a Quant-iT PicoGreen dsDNA
Assay kit (Invitrogen, Carlsbad, CA, USA; catalogue num-
ber P11496) and a SpectraMax Gemini XPS/EM Fluores-
cence Microplate Reader (Molecular Devices, Sunnyvale,
CA, USA). The RNA samples were quantified and
assessed for integrity using the Agilent Bioanalyzer 2100
with RNA 6000 Nano kit (Agilent Technologies, Santa
Clara, CA, USA; catalogue number 5067-1511). The RIN
(RNA integrity number) values of the RNA samples used
for cDNA amplification were ≥8.
Liquid chromatography-mass spectrometry
In order to achieve monomers, 100 ng of each DNA
sample were treated with DNA Degradase Plus (ZymoRe-
search, Irvine, CA, USA; catalogue number E2020) accord-
ing to the manufacturer’s instructions. In parallel, 12
calibration samples containing 0.3125% to 10% 5mC and
0.0625% to 1% 5hmC were prepared from 5-Methylcyto-
sine and 5-Hydroxymethylcytosine DNA Standard Sets
(ZymoResearch, catalogue number D5405). The standards
were degraded to monomers in the same manner as the
DNA samples. Prepared samples were placed into the auto
sampler and 5 μl of samples were injected onto the
LC-MS system.
Quantification of C, 5mC and 5hmC was accomplished
using an Agilent UPLC 1290 system coupled to an Agilent
6460 triple quadrupole (QQQ) equipped with JetStream
electrospray ionization (ESI). Chromatographic separation
was performed on a Waters Atlantis T3 (C18, 3 μm parti-
cles, 100 mm length × 2.1 mm inner diameter; Waters,
Milford, MA, USA) at a flow rate of 300 µl/minute and
17°C. Mobile phase A consisted of 10 mM ammonium
acetate in MilliQ water, and mobile phase B consisted of
10 mM ammonium formate in methanol with 0.1% (v/v)
formic acid. The initial mobile phase composition was 0%
of B for 10.2 minutes. From 10.2 to 13.0 minutes, mobile
phase B was increased to 20%, and held for 1 minutes.
From 14.1 minutes, mobile phase B was decreased to 0%
and held until 19.0 minutes.
Mass spectrometric detection was carried out using
6460 QQQ in positive ion multiple reaction monitoring
mode. The first quadrupole (Q1) was set to transmit the
[M+H]+ ions of the analytes and Q3 was set to transmit
selected fragment ions of analytes. Multiple reaction
monitoring conditions, such as dwell time, Fragment
and CE, are given in Table S1 in Additional file 1. The
sheath gas heater was set to 350°C, gas flow was 5 (l/
minute) and the sheath gas flow was 10. The instrument
was controlled by Mass Hunter Workstation software
(Agilent Technologies). 5mC and 5hmC contents were
calculated based on the calibration curve constructed by
serial standard samples (the standard samples were run
twice, before and after real sample analysis). The linear
fits of determined area over standard amounts ratio
gave R2 values of 0.99981 for 5mC and 0.99941 for
5hmC (Figure S1 in Additional file 1).
Immunohistochemistry
Sections (40 μm) of snap frozen liver were cut with a
microtome cryostat (Cryo-Star HM 560M, MICROM
International GmbH, Walldorf, Germany) and fixated in
4% formaldehyde. The denaturation of sections was
accomplished by treating the tissues with 1 M HCl for
30 minutes at 37°C. Subsequently, the sections were
neutralized by incubating them in 100 mM Tris-HCl
(pH 8.5) for 10 minutes. As primary antibodies, a rabbit
polyclonal antibody to 5hmC (1:5,000; ActiveMotif,
Carlsbad, CA, USA; catalogue number 39769) and a
mouse monoclonal antibody to 5mC (1:500; ActiveMo-
tif, catalogue number 39649) were used. For secondary
antibodies, we used a goat antibody to rabbit Alexa 647
(1:500; Invitrogen, Carlsbad, CA, USA; catalogue num-
ber A21244) and a rabbit antibody to mouse Alexa 488
(1:500; Invitrogen, catalogue number A11059). Samples
were counter-stained with the fluorescent nuclear dye
4’,6-diamidino-2-phenylindole included in the ProLong®
Gold Antifade Reagent mounting media (Invitrogen, cat-
alogue number P-36931). Three-dimensional images
were visualized with a Zeiss confocal microscope and
ZEN 2009 software. No processing of the images was
performed.
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cDNA synthesis and real-time PCR
cDNA was obtained from 1 µg of each total RNA sam-
ple using Superscript III First-Strand Synthesis System
(Invitrogen, catalogue number 18080-051). Real-time
PCR was done with PerfeCTa SYBR Green SuperMix,
Low ROX (Quanta Biosciences, Gaithersburg, MD; cata-
logue number 95056-500) on an ABI 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA,
USA). Relative expression values were calculated from
Ct values using the ΔΔCt method. The housekeeping
gene EIF2B2 was used for the normalization of expres-













The TargetAmp™-Nano Labeling Kit for Illumina®
Expression BeadChip (Epicentre Biotechnologies, Madi-
son, WI, USA; catalogue number TAN07924) was used
to amplify and biotinylate the RNA samples, according
to the manufacturer’s instructions. For each sample, 750
ng of biotinylated cRNA were hybridized on Illumina
HumanHT-12 v4 BeadChips, according to the standard
protocol. The BeadChips were scanned within 24 h
using a HiScanSQ scanner. The raw signals were
exported using the GenomeStudio software, quantile
normalized and further analyzed in R [40].
Next-generation sequencing
Genomic DNA samples (3 µg in 120 µl) were sonicated
using a Covaris S2 with the following settings: duty
cycle = 10%, intensity = 5, cycles per burst = 200, time
= 6 cycles (60 s each), mode = frequency sweeping, tem-
perature = 4°C. Sonicated DNA was purified with 180 µl
of Agencourt AMPure XP beads (Beckman-Coulter,
Miami, FL, USA; catalogue number A63880) and
assessed for concentration and size distribution with the
DNA 1000 kit (Agilent Technologies, catalogue number
5067-1504) on an Agilent Bioanalyzer 2100. All samples
manifested a size distribution between 100 and 250 bp,
with peak at 150 to 200 bp.
Sheared DNA samples were enriched for the 5hmC-
containing fraction with the Hydroxymethyl Collector
kit (ActiveMotif, catalogue number 55013) following the
manufacturer’s instructions. In parallel, non-enriched
aliquots of sheared DNA were diluted 1:100. 5hmC-
enriched samples and their non-enriched counterparts
were then ligated to TruSeq adapters and PCR amplified
according to the protocol detailed in Text S1 in Addi-
tional file 1. The resultant NGS libraries were assessed
for size distribution with the DNA High Sensitivity kit
(Agilent Technologies, catalogue number 5067-4626) on
an Agilent Bioanalyzer 2100 and quantified using a Agi-
lent QPCR NGS Library Quantification kit for Illumina
Genome Analyzer (Agilent Technologies, catalogue
number G4880A). The 5hmC-enriched adult and fetal
samples were pooled separately and sequenced on two
separate lanes. The control non-enriched samples were
also pooled separately for the fetal and adult samples,
and each pool was sequenced on seven lanes. The flow-
cells (v3) were sequenced on an Illumina HiSeq2000
using paired-end sequencing of 100 bp and 6 bp for the
index read.
Sequencing data analysis
The FASTQ sequences of all samples were aligned to
the reference human genome (NCBI37/hg19) using Bur-
rows-Wheeler Aligner (BWA) [41]. Parameter -q 20 was
used for read trimming, and all reads with mapping
quality <20 were filtered out. Duplicate reads generated
during the PCR amplification were removed using SAM-
tool [42]. 5hmC peak identification was performed using
MACS with the following parameters: tag size = 100;
effective genome size = 2.70e+09; band width = 200;
model fold = 10, 30; P-value cutoff = 1.00e-05; ranges
for calculating regional lambda = 1,000 bp and 10,000
bp [43]. The data discussed in this publication have
been deposited in NCBI’s Gene Expression Omnibus
and are accessible through GEO Series accession num-
ber GSE49291 [44].
All subsequent steps of data analysis were done using
custom Python3 scripts, which are available on request.
The coordinates of genomic features were downloaded
from the UCSC Table Browser (tables refGene, lincR-
NAsTranscripts, cpgIslandExt, rmsk, wgEncodeB-
roadHmmHepg2HMM). The coordinates of 5hmC
peaks in human cerebellum were downloaded as Supple-
mentary Data Set 10 of the original paper of Szulwach
and co-authors [30] and converted to Hg19 using the
Galaxy LiftOver tool [45]. The relative enrichment of
5hmC elements in different functional categories of
genes was evaluated using the Genomic Regions Enrich-
ment of Annotations Tool (GREAT) [46], setting the
basal gene regulatory domains within 5 Kb upstream
and 1 Kb downstream of the transcription start site, and
up to 1 Mb extended regulatory domains in both direc-
tions to the nearest gene’s basal domain [47].
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Locus-specific validation of next-generation sequencing
data
To validate NGS data at single-base resolution in
selected genomic intervals, we employed the TAB-Seq
method [48]. Briefly, 1 µg of DNA was oxidized with
the WiseGene 5hmC TAB-Seq kit (WiseGene, Chicago,
IL, USA) following the manufacturer’s instructions [49].
Then, both the oxidized DNA and the corresponding
untreated 500 ng aliquots were bisulfite converted with
EZ DNA Methylation-Gold kit (ZymoResearch, catalo-
gue number D5005), and the resultant DNA samples




TAAATCATTCCTCCC. To increase the specificity of
amplification, the first-round PCR products were puri-
fied, diluted 1:10,000 and amplified again with the




CCC. The second-round PCR products were purified
and subjected to direct Sanger sequencing (Eurofins
MWG Operon, Ebersberg, Germany) [50]. The C/(C+T)
ratios from the oxidized samples reflect the 5hmC
values, whereas such ratios from corresponding non-
oxidized aliquots are equal to the sum of 5mC and
5hmC at the same CpG sites. Hence, the subtraction of
the resultant C/(C + T ratios) permits the calculation
the 5mC and 5hmC values for each CpG site.
Additional material
Additional file 1: Text S1 (the detailed NGS library preparation
protocol), Figures S1 to S5 and Tables S1 to S4.
Additional file 2: Tab-delimited text file describing all 5hmC blocks
discovered in the epigenomes of fetal livers. Fields 1 to 3 contain
genomic coordinates (Hg19) of each 5hmC block. Field 4 indicates the
number of 5hmC-positive samples in a given age cohort (that is, those
samples that manifest a 5hmC peak in a given genomic interval). Fields 5
and 6 provide some metrics of 5hmC occupancy of given 5hmC blocks;
field 5 indicates the sum of 5hmC peak lengths (bp), whereas field 6 shows
the sum of NGS reads in 5hmC peaks among all 5hmC-positive samples.
Additional file 3: Tab-delimited text file describing all 5hmC blocks
discovered in the epigenomes of adult human livers. Fields 1 to 3
contain genomic coordinates (Hg19) of each 5hmC block. Field 4
indicates the number of 5hmC-positive samples in a given age cohort
(that is, those samples that manifest a 5hmC peak in a given genomic
interval). Fields 5 and 6 provide some metrics of 5hmC occupancy of
given 5hmC blocks; field 5 indicates the sum of 5hmC peak lengths (bp),
whereas field 6 shows the sum of NGS reads in 5hmC peaks among all
5hmC-positive samples.
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